Invention Grant
- Patent Title: Inhibiting Eph B-3 kinase
- Patent Title (中): 抑制Eph B-3激酶
-
Application No.: US13260990Application Date: 2010-03-30
-
Publication No.: US08927545B2Publication Date: 2015-01-06
- Inventor: Lixin Qiao , Marcie Glicksman , Thomas Gainer , Donald C. Lo , Ross L. Stein , Sungwoon Choi , Gregory D. Cuny
- Applicant: Lixin Qiao , Marcie Glicksman , Thomas Gainer , Donald C. Lo , Ross L. Stein , Sungwoon Choi , Gregory D. Cuny
- Applicant Address: US NC Durham US MA Boston
- Assignee: Duke University,The Brigham and Women's Hospital, Inc.
- Current Assignee: Duke University,The Brigham and Women's Hospital, Inc.
- Current Assignee Address: US NC Durham US MA Boston
- Agency: Fish & Richardson P.C.
- International Application: PCT/US2010/029209 WO 20100330
- International Announcement: WO2010/117787 WO 20101014
- Main IPC: A61K31/535
- IPC: A61K31/535 ; C07D491/02 ; C07D498/02 ; C07D513/02 ; C07D515/02 ; A61K31/437 ; A61K31/00

Abstract:
EphB3 kinase inhibitor compounds, including certain pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine compounds, inhibit EphB3 kinase. The EphB3 kinase inhibitor compounds can have greater potency for the inhibition of EphB3 kinase than general kinase inhibitors. Pharmaceutical compositions, such as neuroprotective agents, comprising the EphB3 kinase inhibitor compounds are also provided. The EphB3 kinase inhibitor compounds and pharmaceutical compositions are useful, for example, to provide neuroprotection and/or repair of neuronal tissue damaged during an ischemic event, such as a stroke.
Public/Granted literature
- US20120238597A1 Inhibiting EPH B-3 Kinase Public/Granted day:2012-09-20
Information query